Moreover, we found that BC patients who were ER-negative and PR-negative had higher risk scores (both p<0.001), while patients with Luminal A subtype had lower risk scores compared to those with Luminal B, HER2-enriched, and Basal-like subtypes (all p<0.05). This evidence concerns the gene PGR and breast cancer.